Skip to contentR
Resmed Inc
R
RMDResmed Inc Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.46B$1.46Bderived+8.6% vs Q4 2025 Net Income$383.43M$383.43Mderived+1.0% vs Q4 2025 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Resmed Inc · CIK 943819 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$861,216,000+5.0% Operating Incomederived$448,708,000−1.3% Operating Cash Flowderived$454,631,000−15.6% Free Cash Flowderived$403,504,000−20.6% Margins · derivedGross margin58.8%−2.0 pt vs Q4 2025
Operating margin30.7%−3.1 pt vs Q4 2025
Net margin26.2%−2.0 pt vs Q4 2025
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end